Oncotarget · 2017 · 17 citations · 32 references
MedicineOncologyPathologyCancer GeneticsMolecular OncologyMolecular PathologyCancer GenomicsCancer Molecular DiagnosticsCancer Molecular PathologyMalignant NeoplasmsMolecular Tumor ProfilingNext-generation Sequencing In OncologyClinical Next-generation SequencingGenomic Alteration ProfilingNext-generation Sequencing-based DetectionTumor Mutational ProfilingTumor Profiling
// Julie A. Vendrell 1, * , David Grand 2, * , Isabelle Rouquette 2 , Valérie Costes 1 , Samira Icher 2 , Janick Selves 2 , Marion Larrieux 1 , Aurore Barbe 2 , Pierre Brousset 2, 5, ** and Jérôme Solassol 1, 3, 4, 6, ** 1 CHU Montpellier, Arnaud de Villeneuve Hospital, Department of Pathology, Montpellier, France 2 Department of Pathology, Institut Universitaire du Cancer Toulouse Oncopole, CHU de Toulouse, Toulouse, France 3 IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France 4 INSERM, Montpellier, France 5 Laboratoire d’excellence Labex TOUCAN, Toulouse, France 6 Université de Montpellier, Montpellier, France * These authors have contributed equally to this work ** Equal senior contributors Correspondence to: Jérôme Solassol, email: j-solassol@chu-montpellier.fr Keywords: NGS cancer panel, molecular diagnosis, targeted therapies, routine practice Received: July 20, 2016     Accepted: January 23, 2017     Published: March 03, 2017 ABSTRACT Next-generation sequencing (NGS) has revolutionized the therapeutic care of patients by allowing high-throughput and parallel sequencing of large numbers of genes in a single run. However, most of available commercialized cancer panels target a large number of mutations that do not have direct therapeutic implications and that are not fully adapted to low quality formalin-fixed, paraffin-embedded (FFPE) samples. Here, we designed an amplicon-based NGS panel assay of 16 currently actionable genes according to the most recent recommendations of the French National Cancer Institute (NCI). We developed a panel of short amplicons (<150 bp) using dual-strand library preparation. The clinical validation of this panel was performed on well-characterized controls and 140 routine diagnostic samples, including highly degraded and cross-linked genomic DNA extracted from FFPE tumor samples. All mutations were detected with elevated inter-laboratory and inter-run reproducibility. Importantly, we could detect clinically actionable alterations in FFPE samples with variant allele frequencies as low as 1%. In addition, the overall molecular diagnosis rate was increased from 40.7% with conventional techniques to 59.2% with our NGS panel, including 41 novel actionable alterations normally not explored by conventional techniques. Taken together, we believe that this new actionable target panel represents a relevant, highly scalable and robust tool that is easy to implement and is fully adapted to daily clinical practice in hospital and academic laboratories.
32
Fabrice Barlési, Julien Mazières, Jean‐Philippe Merlio et al. · The Lancet · 2016 · 984 citations
Precision Oncology: An Overview
Levi A. Garraway, Jaap Verweij, Karla V. Ballman · Journal of Clinical Oncology · 2013 · 403 citations · Full text
Medicine, Cancer Biology, Oncology +15